Abstract The global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and the high prevalence among individuals with type 2 diabetes has attracted the attention of clinicians specialising in liver disorders
Authors contributions Conception of the consensus statement: ADO, LJO, JIMA, BJS, DLH Data extraction: LJO, AS, JMIA, KDK, ES, CRFR, RC Interpretation of data: ADO, LJO, BJS, AS, JMIA, KDK, ES, CRFR, RC, MDHA, CEM, MC, RM, GEU, DLH Writing the manuscript: ADO, LJO, AS, JMIA, MDHA, KDK, ES, CRFR, RC Revising the manuscript for important intellectual content: ADO, BJS, MC, RM, GEU, DLH Declarations of interest GEU receives grant support from Novo Nordisk, Merck, Insulcloud, Dexcom, Abbott, AstraZeneca, and Bayer
[5] Topical GHK-Cu is generally considered well tolerated, yet therapy should be avoided in individuals with a known hypersensitivity to copper peptides or any vehicle component
NAD+ injections provide a quicker, lower-dose option and are commonly used for maintenance or ongoing support between infusions
Limitations of the study should be considered
Da wir mit Lebensmittel und krpereigener Synthese zwei Carnitin-Quellen besitzen, kann es bei einer zustzlichen Gabe von Supplementen ber eine lngere Zeit zu einer berdosis kommen
